Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 3, 2006, Pages 363-366

  Putzki, Norman ^a,c   Knipp, Sabine ^b   Ramczykowski, Tim ^a   Vago, Susanne ^a   Germing, Ulrich ^b   Diener, H Chr ^a   Limmroth, Volker ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Azathioprine; Multiple sclerosis; Myelodysplastic syndrome; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW TRANSPLANTATION; BREAST CARCINOMA; CAUSE OF DEATH; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG FATALITY; DRUG MONITORING; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; RISK ASSESSMENT; SUICIDE; TESTIS TERATOMA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33744793988     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1307cr     Document Type: Article

References (10)

1. Rieckmann P, Toyka KV, MSTCG. Escalating immunotherapy of multiple sclerosis. New aspects and practical application. J Neurol 2004; 251: 1329-39.
2. Lhermitte F, Marteau R, Roullet E, de Saxce H, Loridan M. Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience. Rev Neurol 1984; 140: 553-58.
3. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44-49.
4. Confavreux C, Saddler P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607-12.
5. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002; 12: 2177-85.
6. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatic arthritis. Ann Rheum Dis 1988; 57: 503-505.
7. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005; 90: 691-93.
8. Willerding-Mollmann S, Wilkens L, Schlegelberger B, Kaiser U. Azathioprine associated myelodysplastic syndrome with cytogenic abnormalities. Deutsch Med Wochenschr 2004; 129: 1246-48.
9. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1975-2001. Leukemia 2002; 16: 2366-78.
10. Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology 2004; 63: 41-46.